Antidiabetic Agents: Medications such as glucagon-like peptide 1 (GLP-1) agonists and Dipeptidyl peptidase 4 (DPP-4) inhibitors may offer neuroprotective effects in PD by reducing neuroinflammation and oxidative stress [73,74,75]. This evidence concerns the gene DPP4 and Parkinson disease.